Microlyte® – Next Generation Wound Care

 

SAMatrix™ Technology has the ability to integrate various agents to be a one-product solution, facilitating multiple steps across the wound healing process.

A fully synthetic and porous matrix composed of bioresorbable polymers, SAMatrix™ immediately conforms to micro-textures of the wound with full transparency.1-3

It facilitates a cytophilic, non-pyrogenic, moist wound-healing environment that allows for cells to attach, adhere, migrate and proliferate.1-3

The matrix contains ionic and metallic silver at a low, non-toxic level, providing at least 72 hours of sustained, 99.99% reduction in microbial burden.4†

Get in Touch

 

Microlyte® is indicated for:

  • Partial and full-thickness chronic wounds, including pressure ulcers, venous stasis ulcers, diabetic foot ulcers;
  • Surgical wounds, including donor sites, use over debrided and grafted partial thickness wounds, post Moh’s surgery, post laser surgery, podiatry, dehisced wounds;
  • Traumatic wounds, including first and second-degree burns, abrasions, lacerations, skin tears.

Debridement and removal of necrotic tissue is recommended before matrix placement.

Laboratory and pre-clinical studies indicate that the components of the matrix allow for healthy cell and new blood vessel growth in wounds. The metallic and ionic silver allows for the sustained release of antimicrobial activity. This product can be used with other adjunctive therapies.

 

United States SKUs

HCPCS Product Code: A2005 – Microlyte® Matrix, per sq cm.

Available in a range of sizes to manage a wide variety of wound types, minimizing product waste. All products are sterile and individually packaged.

 

Outside of United States SKUs

Microlyte®

Clinically Proven

Published clinical data in the November 2020 edition of WOUNDS journal shows the clinical results of using Microlyte® for chronic wounds. Thirty-two patients with various chronic wounds were evaluated.  All wounds were non-healing for a median of 39 weeks (range, 3-137 weeks).

At 3 weeks:  79% closure in responsive DFU patients. 60% closure in responsive venous stasis ulcers. 72% of all wounds had significantly improved healing with an average wound area reduction of 66%.

At 12 weeks:  91% of wounds either healed completely or improved significantly with an average wound area reduction of 73%. 

The application of Microlyte® was safe and well tolerated, and it facilitated improvements in healing of a majority of the complex chronic wounds studied.8  

Read the full WOUNDS article

Get in Touch

HCP Information Request

Complete this form to receive more information about Imbed Biosciences’ products.

This field is for validation purposes and should be left unchanged.
Name(Required)
Email(Required)
Facility type(Required)
In which settings do you practice? Click all that apply.
In which state do you practice? If international, indicate country in comment section.
Product line
What product line(s) are you interested in? Click all that apply.
How did you hear about us?(Required)

Distributor Information Request

Complete this form to receive information about representing Imbed Biosciences products in your accounts.

This field is for validation purposes and should be left unchanged.
Name(Required)
Email(Required)
If in the United States.
If outside the United States.
Facility type(Required)
What markets do you serve? Click all that apply.
Product line(Required)
What product line(s) are you interested in? Click all that apply.
Please tell us about your distributorship and how Imbed Biosciences products may fit.
How did you hear about us?(Required)

Related Products

Pelashield®

Pelashield® is a fully synthetic, hydrophilic, antimicrobial matrix specifically designed for complex challenges in burn and acute wounds.1 Learn how Pelashield® can help with the complex challenges of burn and acute wounds.

Surgaflex®

Surgaflex® is is a fully synthetic, ultrathin and low profile antimicrobial polymer matrix designed for use in acute and surgical wounds.1,2,3 Learn how Surgaflex® can help manage surgical wounds to improve outcomes.